Review


DOI :10.26650/jchild.2020.3.780358   IUP :10.26650/jchild.2020.3.780358    Full Text (PDF)

Pathogenesis and Biology of Graft-Versus-Host Disease

Demet Kıvanç İzgiFatma Savran Oğuz

Graft-versus-host disease (GvHD) is an important complication that usually develops after hematopoietic stem cell transplantation and affects the success of the transplant. It is important to identify the pathogenesis, risk factors, prognosis, and biomarkers for the management and prevention of GvHD, as welll as the development of treatment strategies for GvHD. This review presents current literature studies on factors that affect GvHD biology, including classical and nonclassical human leukocyte antigen (HLA) genes, minor HLA antigens, cytokines, chemokines, and costimulatory molecules.

DOI :10.26650/jchild.2020.3.780358   IUP :10.26650/jchild.2020.3.780358    Full Text (PDF)

GvHH Patogenezi ve Biyolojisi

Demet Kıvanç İzgiFatma Savran Oğuz

Graft versus host hastalığı (GvHH) genellikle hematopoetik kök hücre nakli (HKHN) sonrası gelişen ve nakil işleminin başarısını etkileyen önemli bir komplikasyondur. GvHH’nin iyi yönetilmesi, önlenmesi ve tedavi stratejilerinin geliştirilebilmesi için patogenezi, risk faktörleri, prognozu ve biyobelirteçlerinin tespit edilmesi önemlidir. Bu derlemede GvHH biyolojisinde etkili olan faktörlerden klasik ve klasik olmayan insan lökosit antijenleri (HLA) genleri, minör HLA antijenleri, sitokinler, kemokinler ve kostimülatör moleküller ile ilgili literatürde yer alan güncel çalışmalar sunulmuştur.


PDF View

References

  • 1. Ferrara JL, Reddy P. Pathophysiology of graft versus-host disease. Semin Hematol 2006;43(1):3-10. google scholar
  • 2. Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020 Feb;7(2):e157-e167. google scholar
  • 3. Carpenter PA, MacMillan ML. Management of acute graft-versus-host disease in children. Pediatr Clin North Am 2010 Feb;57(1):273-95. google scholar
  • 4. Patel KK, Patel AK, Ranjan RR, Shah AP. Transfusion associated graft versus host disease following whole blood transfusion from an unrelated donor in an ımmunocompetent patient. Indian J Hematol Blood Transfus 2010 Sep;26(3):92-5. google scholar
  • 5. Saffo S, Peng C, Kibbi N, Patel N, Robert ME, Adekolu E, et al. Graftversus- host disease after pancreatic transplantation. ACG Case Rep J 2019 Sep 12;6(9):e00214. google scholar
  • 6. Batra A, Cottler-Fox M, Harville T, Rhodes-Clark BS, Makhoul I, Nakagawa M. Autologous graft versus host disease: An emerging complication in patients with multiple myeloma Bone Marrow Res 2014;2014:891427. google scholar
  • 7. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012 Jan 5;119(1):296-307. google scholar
  • 8. Billingham RE. The biology of graft-versus-host reactions. Harvey Lectures 1966-67;62:21-78. google scholar
  • 9. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003 Jul 15;102(2):756-62. google scholar
  • 10. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005 Dec;11(12):945-56. google scholar
  • 11. Pavletic SZ, Vogelsang GB, Lee SJ. 2014 National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Preface to the series. Biol Blood MarrowTranspl 2015 Mar;21(3):387-8. google scholar
  • 12. Apostolova P, Zeiser R. The role of danger signals and ectonucleotidases in acute graft-versus- host disease. Hum Immunol 2016 Nov;77(11):1037-47. google scholar
  • 13. Zeiser R, Penack O, Holler E, Idzko M. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med(Berl) 2011 Sep;89(9):833-45. google scholar
  • 14. Reddy P. Pathopysiology of acute graft versus host disease. Hematol Oncol 2003 Dec:21(4):149-61. google scholar
  • 15. Sung AD, Chao NJ. Acute graft-versus-host disease: Are we close to bringing the bench to the bedside? Best Pract Res Clin Haematol 2013 Sep;26(3):285-92. google scholar
  • 16. Yu Y, Wang D, Liu C, Kaosaard K, Semple K, Anasetti C, et al. Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice. Blood 2011 Nov 3;118(18):5011-20. google scholar
  • 17. Socié G, Ritz J. Current issues in chronic graft-versus-host disease. Blood 2014 Jul 17;124(3):374-84. google scholar
  • 18. Sarantopoulos S, Ritz J. Aberrant B-cell homeostasis in chronic GVHD. Blood 2015 Mar 12;125(11):1703-7. google scholar
  • 19. Zeiser R, Blazar BR. Pathophysiology of chronic graft versus host disease and therapeutic targets. N Engl J Med 2017 Dec 28;377(26):2565-2579. google scholar
  • 20. Ghimire S, Weber D, Mavin E, Wang, XN, Dickinson, AM, Holler, E. Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol 2017 Mar 20;8:79. google scholar
  • 21. Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, et al. Influence of age on acute and chronic GVHD in children undergoing HLA-identical sibling bone marrow transplantation for acute leukemia: Implications for prophylaxis. Biol Blood MarrowTransplant 2018 Mar;24(3):521-8. google scholar
  • 22. Vignon M, Andreoli A, Dhédin N, Lebgline E, Masson E, Robin M, et al. Graft-versus-host disease in adolescents and young adults (15-24 years old) after allogeneic hematopoietic stem cell transplantation for acute leukemia in first complete remission. J Adolesc Young Adult Oncol 2017 Jun;6(2):299-306. google scholar
  • 23. Carlberg V, Simons E, Delano S, Huang JT. Pediatric Graft- Versus-Host Diease In: Cotliar JA, eds. Atlas of Graft-Versus-Host Diease: Approaches to Diagnosis and Treatment. Cham, 1st ed. Switzerland: Springer International Publishing AG, 2017:105-23. google scholar
  • 24. Gatza E, Reddy P, Choi SW. Prevention and treatment of acute graftversus- host disease in children, adolescents, and young adults. Biol Blood Marrow Transplant 2020 May;26(5):e101-e112. google scholar
  • 25. Hosseini E, Schwarer AP, Ghasemzadeh M. The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation. Iran J Allergy Asthma Immunol 2012;11(1):15-21. google scholar
  • 26. Hosseini E, Schwarer AP, Ghasemzadeh M. Do human leukocyte antigen E polymorphisms influence graft-versus-leukemia after allogeneic hematopoietic stem cell transplantation? Exp Hematol 2015 Mar;43(3):149-57. google scholar
  • 27. The IMGT/HLA Database; http://www.ebi.ac.uk/imgt/hla/stats. html Erişim tarihi: 27.03.2014 google scholar
  • 28. Meyer D, Aguriar VRC, Bitarello BD, Brandt DYC, Nunes K. A genomic perspective on HLA evolution. Immunogenetics 2018 Jan;70(1):5-27. google scholar
  • 29. Edgerly CH, Weimer ET. The Past, present, and future of HLA typing in transplantation. Methods Mol Biol 2018;1802:1-10. google scholar
  • 30. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-resolution donor recipient HLA matching contributest othe success of unrelated donor marrow transplantation. Blood 2007 Dec 15;110(13):4576-83. google scholar
  • 31. Touzeau C, Gagne K, Sebille V, Herry P, Chevallier P, Follea G, et al. Investigation of the impact of HLA-DPB1 matching status in 10/10 HLA matched unrelated hematopoietic stem cell transplantation: results of a French single center study. Hum Immunol 2012 Jul;73(7):711-4. google scholar
  • 32. Crocchiolo R, Zino E, Vago L, Oneto R, Bruno B, Pollichieni S, et al. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. Blood 2009 Aug 13;114(7):1437-44. google scholar
  • 33. Rene C, Lozano C, Eliaou JF. Expression of classical HLA class I molecules: regulation and clinical impacts: Julia Bodmer award review 2015. HLA 2016 May;87(5):338-49. google scholar
  • 34. Summers C, Sheth VS, Bleakley M. Minor histocompatibility antigen-specific T cells. Front Pediatr 2020 Jun3;8:284. google scholar
  • 35. Roy DC, Perreault C. Major vs minor histocompatibility antigens. Blood 2017 Feb 9;129(6):664-6. google scholar
  • 36. Akatsuka Y, Warren EH, Gooley TA, Brickner AG, Lin MT, Hansen JA, et al. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol 2003 Nov;123(4):671-5. google scholar
  • 37. McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, et al. Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet 2009 Dec;41(12):1341-4. google scholar
  • 38. Martin PJ, Levine DM, Storer BE, Warren EH, Zheng X, Nelson SC et al. Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease. Blood 2017 Feb 9;129(6):791-8. google scholar
  • 39. Mohty M, Blaise D, Faucher C, Vey N, Bouabdallah R, Stoppa AM, et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005 Dec 15;106(13):4407-11. google scholar
  • 40. Henden AS, Hill GR. Cytokines in graft-versus-host disease. J Immunol 2015 May 15;194(10):4604-12. google scholar
  • 41. Kumar S, Mohammadpour H, Cao X. Targeting cytokines in GVHD therapy. J Immunol Res Ther 2017;2(1):90-9. google scholar
  • 42. Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D, et al. Reciprocal differentiation and tissue- specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood 2009 Oct 1;114(14):3101-12. google scholar
  • 43. Hüber CM, Doisne JM, Colucci F. IL-12/15/18-preactivated NK cells suppress GvHD in a mouse model of mismatched hematopoietic cell transplantation. Eur J Immunol 2015 Jun;45(6):1727-35. google scholar
  • 44. Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe AH, Noelle RJ, Rudensky AY, et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 2005 Apr 15;105(8):3372-80. google scholar
  • 45. Zeiser R, Blazar BR. Acute graft versus host disease-biologic process, prevention and therapy. N Engl J Med 2017 Nov 30;377(22):2167- 79. google scholar
  • 46. Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 2019 Jan;25(1):94-9. google scholar
  • 47. Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman E, et al. PD-1 blockade for relapsed lymphoma postallogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 2017 Jul 13;130(2):221-8. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Kıvanç İzgi, D., & Savran Oğuz, F. (2020). Pathogenesis and Biology of Graft-Versus-Host Disease. Journal of Child, 20(3), 115-119. https://doi.org/10.26650/jchild.2020.3.780358


AMA

Kıvanç İzgi D, Savran Oğuz F. Pathogenesis and Biology of Graft-Versus-Host Disease. Journal of Child. 2020;20(3):115-119. https://doi.org/10.26650/jchild.2020.3.780358


ABNT

Kıvanç İzgi, D.; Savran Oğuz, F. Pathogenesis and Biology of Graft-Versus-Host Disease. Journal of Child, [Publisher Location], v. 20, n. 3, p. 115-119, 2020.


Chicago: Author-Date Style

Kıvanç İzgi, Demet, and Fatma Savran Oğuz. 2020. “Pathogenesis and Biology of Graft-Versus-Host Disease.” Journal of Child 20, no. 3: 115-119. https://doi.org/10.26650/jchild.2020.3.780358


Chicago: Humanities Style

Kıvanç İzgi, Demet, and Fatma Savran Oğuz. Pathogenesis and Biology of Graft-Versus-Host Disease.” Journal of Child 20, no. 3 (Mar. 2024): 115-119. https://doi.org/10.26650/jchild.2020.3.780358


Harvard: Australian Style

Kıvanç İzgi, D & Savran Oğuz, F 2020, 'Pathogenesis and Biology of Graft-Versus-Host Disease', Journal of Child, vol. 20, no. 3, pp. 115-119, viewed 28 Mar. 2024, https://doi.org/10.26650/jchild.2020.3.780358


Harvard: Author-Date Style

Kıvanç İzgi, D. and Savran Oğuz, F. (2020) ‘Pathogenesis and Biology of Graft-Versus-Host Disease’, Journal of Child, 20(3), pp. 115-119. https://doi.org/10.26650/jchild.2020.3.780358 (28 Mar. 2024).


MLA

Kıvanç İzgi, Demet, and Fatma Savran Oğuz. Pathogenesis and Biology of Graft-Versus-Host Disease.” Journal of Child, vol. 20, no. 3, 2020, pp. 115-119. [Database Container], https://doi.org/10.26650/jchild.2020.3.780358


Vancouver

Kıvanç İzgi D, Savran Oğuz F. Pathogenesis and Biology of Graft-Versus-Host Disease. Journal of Child [Internet]. 28 Mar. 2024 [cited 28 Mar. 2024];20(3):115-119. Available from: https://doi.org/10.26650/jchild.2020.3.780358 doi: 10.26650/jchild.2020.3.780358


ISNAD

Kıvanç İzgi, Demet - Savran Oğuz, Fatma. Pathogenesis and Biology of Graft-Versus-Host Disease”. Journal of Child 20/3 (Mar. 2024): 115-119. https://doi.org/10.26650/jchild.2020.3.780358



TIMELINE


Submitted14.08.2020
Accepted03.11.2020
Published Online30.12.2020

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.